[{"id":"c29522a3-7871-451f-9b15-79b2e1027e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084286","created_at":"2023-10-16T15:12:50.114Z","updated_at":"2024-07-02T16:35:33.444Z","phase":"Phase 1","brief_title":"Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT06084286","lead_sponsor":"Sichuan University","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-10-16"},{"id":"2d21c882-cdc1-4530-9199-80424963a3ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03060343","created_at":"2021-01-18T15:04:23.452Z","updated_at":"2024-07-02T16:37:25.127Z","phase":"Phase 1","brief_title":"Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03060343","lead_sponsor":"Yu Fenglei","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zeushield cytotoxic T lymphocyte therapy"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 11/28/2016","start_date":" 11/28/2016","primary_txt":" Primary completion: 11/28/2018","primary_completion_date":" 11/28/2018","study_txt":" Completion: 11/28/2019","study_completion_date":" 11/28/2019","last_update_posted":"2017-02-23"},{"id":"eeb431e7-19d7-4c60-b848-39198bf15658","acronym":"","url":"https://clinicaltrials.gov/study/NCT02930967","created_at":"2021-01-18T14:23:36.991Z","updated_at":"2024-07-02T16:37:28.518Z","phase":"Phase 1","brief_title":"Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors","source_id_and_acronym":"NCT02930967","lead_sponsor":"China Meitan General Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • anti-PD-L1 CSR T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2016-10-12"}]